Halozyme Therapeutics Inc. has entered into a global exclusive collaboration and license agreement with Vertex Pharmaceuticals Incorporated, through which Vertex has licensed Halozyme’s Hypercon technology for use in up to three drug targets. Hypercon is a microparticle technology that allows for hyperconcentration of drugs and biologics, thus reducing injection volume for the same dosage and enabling convenient, at-home administration. “This collaboration with Vertex underscores ...